novel and improved approaches for cancer control in this Squamous cell carcinomas (SCC) induced in hamster anatomical region requires the utilization of appropriate buccal pouch (HBP) by 22 weeks of topical N-methyl-Nexperimental models (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . In this regard, chemical carcinobenzylnitrosamine (MBN) treatment (twice-weekly, 10 mg genesis in the hamster buccal pouch (HBP) appears to be a MBN/ml propylene glycol) were evaluated for: (i) altered particularly relevant in vivo model (8, 9, (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . The developexpression of p53 using immunohistochemistry (IHC); (ii) ment of squamous cell carcinoma (SCC) in HBP during mutations in Ha-ras and p53 using PCR/single strand exposure to specific chemical carcinogens recapitulates all of conformation polymorphism (SSCP); (iii) telomerase the structural (19) (20) (21) ) and many of the biological (8,24-29) activity using the telomerase repeat amplification and molecular alterations (8, 23, 24, 27, (30) (31) (32) (33) (34) which occur protocol (TRAP). Precancerous lesions were also evaluated during head and neck carcinogenesis in humans voluntarily using p53 IHC. Hamsters were killed for lesion analysis at exposed to the constituents of tobacco products and alcoholic either 3 days (group A, eight hamsters, 89 carcinomas) or beverages.
weeks (group B, six hamsters, 105 carcinomas) following
Mutations in the p53 (35, 36) and Ha-ras (37) genes and the final MBN application. Between 3 days and 7 weeks activation of the ribonucleoprotein enzyme telomerase (38,39) post-treatment the proportion of tumors exhibiting p53 are among the specific molecular alterations which have been IHC activity (at least 10% of nuclei stained using D07 observed in human cancers of the head and neck. The purpose antibodies for detection of both mutant and wild-type p53) of this study was to characterize carcinomas of the HBP fell from 91 to 50%. However, during this same postinduced by the potent mucosal carcinogen N-methyl-N-benzyltreatment period the frequency of tumors analyzed exhibitnitrosamine (MBN) with regard to telomerase activation, ing confirmed sequence alterations in the conserved exons p53 and Ha-ras mutation and immunohistochemical (IHC) (E5-E8) of p53 remained constant (5/15 ⍧ 33% in group expression of p53 protein. The occurrence of these molecular A versus 14/45 ⍧ 31% in group B). Heightened expression alterations and the IHC expression of p53 in both the carcinof wild-type p53 resulting from DNA damage in the omas and precancerous lesions observed in this animal model immediate post-treatment period is likely to have conresemble those reported for the analogous head and neck tributed to the high proportion of group A tumors lesions of man. The results of this study further advance this exhibiting p53 IHC activity. Nearly 80% of the identified variant of the HBP model as a potential tool for the development p53 mutations were G→A and C→T transitions. The of novel strategies for chemoprevention, diagnosis and treatidentified p53 point mutations occurred at or near (within ment of head and neck cancer. 1% solution (10 mg/ml) of MBN dissolved in propylene glycol (PG) (22) .
Telomerase activation was demonstrated in 11 of 13 group
Two control hamsters were similarly treated topically with PG alone. Induction of wild-type p53 (40,41) and a myriad of other metabolic effects (e.g. induction 
prevention regimens and multimodality cancer therapies.
Three days after the final MBN treatment, eight hamsters were killed and tumor tissues were harvested for IHC analysis and extraction of DNA and protein as described below. Two of the remaining MBN-treated hamsters died unexpectedly in week 6 following carcinogen treatment and could not Abbreviations: HBP, hamster buccal pouch; HBPC, hamster buccal pouch carcinoma; IHC, immunohistochemical; MBN, N-methyl-N-benzylnitrosbe included in the study. The remaining six MBN-treated hamsters were killed during the following week (i.e. week 7) for tumor analysis. At the time of amine; PBS, phosphate-buffered saline; PG, propylene glycol; SCC, squamous cell carcinoma; SSCP, single strand conformation polymorphism; TRAP, death the tumor-bearing pouches were immediately excised, cleansed by thoroughly rinsing twice in cold phosphate-buffered saline (PBS), blotted dry telomerase repeat amplification protocol. and spread out with connective tissue side down on pieces of cardboard. The 3MM paper and vacuum dried at 70°C. Autoradiography was done at -70°C for 2-5 h with Hyperfilm-MP (Amersham, Arlington Heights, IL) (45) . tumors were then enumerated, diagrammed and their maximum dimensions were recorded in 0.5 mm increments. Representative exophytic tumor masses, Alternatively, a silver staining detection system was used in addition to isotopic labeling. For this purpose the amplicons were denatured and comprised predominantly of grayish glistening neoplastic tissue, were identified and individually bisected using a clean blade to avoid cross-contamination of electrophoresed using the GeneGel Excel 12. In cases where band shifts of Ͻ20% were observed, the bands were eluted prepared and stained with hematoxylin and eosin for routine histological from the gel and PCR was repeated prior to direct sequencing. In order to evaluation. Contiguous sections were processed for immunohistochemical obtain unequivocal results, sequencing was routinely performed in both the identification of p53 protein using an indirect immunoperoxidase technique sense and antisense directions. employing the primary monoclonal antibody NCL-p53-D07 (mAb D07; Novocastra, Newcastle, UK) and the avidin-biotin complex method (Vectastain Determination of telomerase activity Elite ABC kit; Vector Laboratories, Burlingame, CA) with 3,3-diaminobenzidTelomerase activity was determined using the telomerase repeat amplification ine substrate. The mAb D07 antibodies detect both wild-type and mutant protocol (TRAP) as described by Kim et al. (46) , with minor modifications forms of p53 (43). Tissue sections mounted on gelatin-chrome alum-coated (47) . Protein extract for TRAP was obtained by the following procedures. slides were deparaffinized in xylene (twice) and rehydrated with a descending Approximately 10 mg of frozen tissue sample was homogenized, mixed with series of absolute, 95%, 70% and 30% ethanol, followed by water. After 100 µl lysis buffer (10 mM Tris-HCl, pH 7.5, 1 mM MgCl 2 , 1 mM EGTA, blocking endogenous peroxidase activity with 1% H 2 O 2 , antigenicity was 0.1 mM phenylmethylsulfonyl fluoride, 5 mM β-mercaptoethanol, 0.5% unmasked by microwave heating for 3 min in a 10 mM solution of CHAPS and 10% glycerol), incubated on ice for 30 min, then the lysate was sodium citrate. A blocking solution of 2% dry milk in PBS (with 0.02% centrifuged at 12 000 g for 30 min at 4°C. The supernatant was repeatedly sodium azide) was applied to reduce non-specific staining. The sections were centrifuged under similar conditions. One microliter of supernatant was used incubated with mAb D07, at a dilution of 1:200, for 2 h at 25°C in a to measure the protein concentration with a Bradford protein assay kit (Pierce, humidification chamber. After rinsing with PBS, the sections were incubated Rockford, IL). Then the protein concentration was adjusted to 3 µg/µl. The with biotinylated anti-mouse IgG antibody for 30 min, washed again with adjusted aliquots were stored at -70°C until use. TRAP analysis was performed PBS and then incubated with avidin-biotin complex conjugated to horseradish as follows. An aliquot of 2 µl of adjusted extract (6 µg, equal to 2ϫ10 4 peroxidase for another 30 min. After a PBS rinse, the sections were stained cultured KB cells) was assessed in a 50 µl reaction mixture containing 2 µl with 1 mg/ml 3,3-diaminobenzidine tetrahydrochloride (Novocastra) and (10 pmol) of TS primer (5Ј-AATCCGTCGAGCAGAGTT-3Ј), 2 µl (10 pmol) 0.30% H 2 O 2 for 1 min. After rinsing with PBS, the slides were washed in of CX primer (5Ј-CCCTTACCCTTACCCTTACCCTAA-3Ј), 5 µl of 10ϫ TS tap water for at least 5 min before counterstaining with hematoxylin. A p53-buffer (0.2 M Tris-HCl, pH 8.3, 15 mM MgCl 2 , 630 mM KCl, 0.05% Tween staining human breast carcinoma sample served as a positive control for p53 20, 10 mM EGTA and 1 mg/ml BSA), 2 µl (10 mM) dNTP, 0.8 µl (5 U/µl) nuclear staining. This same tumor without primary antibody was used as a Taq polymerase (Promega) and 36.2 µl of ddH 2 O overlayed with mineral oil negative control. in a 0.5 ml tube. After 30 min incubation at 25°C to allow formation of TS The proportion (percentage) of tumor cells exhibiting p53 nuclear staining primer-dependent telomerase products, the reaction tube was subjected to was determined by microscopic examination of randomly selected high power 90°C for 3 min to inactivate the telomerase enzyme activity. It was followed fields in each tumor. The average proportion of p53-stained cells was then by 31 cycles of PCR reaction consisting of 94°C for 30 s, 57°C for 30 s and calculated for each tumor and recorded in 10% gradations, as follows: 72°C for 30 s. Then, 25 µl of PCR products were analyzed by electrophoresing 0-Ͻ10% ϭ 0%, ജ10-Ͻ20% ϭ 10%, ജ20-Ͻ30% ϭ 20%, etc. These in a 12.5% non-denaturing polyacrylamide gel and 1ϫ TAE buffer until the determinations were made independently by two pathologists, who typically bromophenol blue dye had reached the lower border of the gel. The gel was agreed within one gradation. When initial determinations were discordant, a then stained with a PlusOne DNA silver staining kit (Pharmacia) in a Hoefer consensus figure was achieved by joint re-examination and evaluation of the automated gel stainer (Pharmacia). Photographic films were obtained by tumors in question. A tumor was recorded as p53-positive when the proportion an image analyzer (Vilber Lourmat) under predetermined conditions (45) . of tumor cells exhibiting nuclear staining was determined to be ജ10%.
Telomerase activity was demonstrated by prominent successive bands (typically DNA isolation and PCR 10 or more). Reproducibility of TRAP data was confirmed by two or more repeat DNA was isolated from tumor samples by conventional proteinase K/phenol/ experiments. Optimization testing demonstrated a proportional relationship chloroform extraction (44). Segments of the hamster p53 gene were amplified between band number and band intensity. To check whether there were in vitro by PCR, as previously described (45), using the oligonucleotide telomerase (or PCR) inhibitors preventing adequate amplification, samples primers shown in Table I .
negative in the TRAP reaction were diluted 10-fold in an attempt to recover A hamster Ha-ras sequence of 161 bp, including exon 1, was amplified telomerase activity. As an additional check for the presence of TRAP inhibitory using the synthetic oligonucleotide hamster-specific primers Ha-ras E1S (5Ј-factors, telomerase-negative extracts were also run in combination with TGGCAGCCTCTATAGAAGC-3Ј) and Ha-ras E1A (5Ј-GCCAGAGCCCApositive extracts (1:1 ratio). To exclude the possibility of DNA contamination GCAGGTAG-3Ј). A hamster Ha-ras sequence of 179 bp, including exon 2, in positive samples, 2 µl samples of extract were incubated with 1 µl RNase was amplified using the hamster-specific primers Ha-ras E2S (5Ј-GACT-A (1 mg/ml) for 20 min at 25°C, then subjected to TRAP assay. A negative CCTACCGGAAACAGGT-3Ј) and Ha-ras E2A (5Ј-CTGTACTGATGGAcontrol (sample-free, lysis buffer only) and a positive control (KB cell extract) TGTCTTC-3Ј). Parameters for amplification were 1 min at 94°C, 1 min at were included with each round of TRAP assay. 55-57°C and 1 min at 72°C for 35 cycles. All amplifications were performed using a TouchDown™ thermal cycling system (Hybaid, Teddington, UK).
Single strand conformation polymorphism (SSCP)

Results
A primary amplification was executed in duplicate as described above with A summary of the results, including tumor frequency and unlabeled primers. Each sense strand was analyzed in a second amplification the proportion of carcinomas exhibiting p53 IHC activity, in which only the sense oligonucleotide was end-labeled with [γ-32 P]ATP (DuPont/New England Nuclear, Wilmington, DE) using T4 polynucleotide frequency of mutations in the p53 and Ha-ras genes and kinase (Promega, Madison, WI). The amplified product with only one strand telomerase activity, is shown in Table II. radioactively tagged was added to a formamide-based loading buffer, denatured and p53 IHC results observed in MBN-induced precancerous application of the vehicle PG, exhibited neither morphological change nor p53 IHC activity. lesions and SCC are shown in Figure 1 . The tumors included well-differentiated and moderately differentiated SCC and A combined total of 60 buccal pouch carcinomas from group A (15 carcinomas) and B (45 carcinomas) hamsters occasional hyperplastic inflammatory lesions. The latter were not included in the tumor analysis. In the group A hamsters, were analyzed by SSCP and DNA sequencing in order to identify specific p53 and Ha-ras mutations (Tables II-V) . evaluated 3 days after the last MBN application, 81 of the 89 carcinomas (91%) exhibited nuclear p53 IHC activity in 10% Approximately 32% of these carcinomas exhibited p53 mutations (Table II) . Representative results for group B or more of the tumor cells. In both group A and B hamsters, patchy p53 IHC activity was also observed throughout the carcinomas, analyzed by SSCP and DNA sequencing of p53 exons 5 and 7, are shown in Figures 3 and 4 , respectively. grossly tumor-free MBN-exposed epithelium. In these areas, p53 activity was observed primarily in sites of microscopic Eleven of the 14 group B carcinomas (i.e. 79%) exhibiting p53 mutations, as determined by either SSCP or a combination hyperplasia, structural precancerous lesions (i.e. dysplasia and carcinoma in situ) and in microinvasive SCC (Figure 1A-D) .
of SSCP and DNA sequencing, also exhibited p53 IHC activity in 10% or more of their constituent cells (see Table III ). The In non-dysplastic areas, p53 IHC activity was usually limited to the basal aspect of the epithelium ( Figure 1A) . specific mutations identified in exons 5-8 of the p53 gene are presented in Table IV . Of the 18 carcinomas wherein specific The proportion of carcinomas exhibiting p53 IHC activity in group B hamsters was 53 of 105 (50%). Thus, the proportion p53 mutations were identified by SSCP and DNA sequencing, G→A and C→T transitions accounted for 44 and 33%, of carcinomas exhibiting p53 IHC activity dropped significantly (P Ͻ 0.001, two-tailed Student's t-test) between 3 days and 7
respectively. Of the 60 carcinomas analyzed by SSCP and DNA weeks after MBN treatment. In general, there was no apparent relationship between the degree of differentiation of the sequencing to identify mutations in the Ha-ras gene, only eight (13%) exhibited a point mutation in this gene. Figures carcinomas and the proportion or intensity of neoplastic cells exhibiting p53 IHC activity. Nor was there a relationship 5 and 6 show representative SSCP/sequencing analyses of Ha-ras gene exons 1 and 2, respectively, in group B buccal between the size of the tumors and the proportion of tumor cells exhibiting p53 IHC activity (Table III and Figure 2) . pouch carcinomas. A summary of the Ha-ras mutation analysis is shown in Table V . Activation of the ras gene family is However, an occasional carcinoma exhibited cellular regions or foci with both a greater degree of cytological atypia and known to occur primarily through mutation at codons 12, 13 and 61 (48, 49) . In three of the eight buccal pouch carcinomas more intense expression of p53 IHC activity than the tumor overall (see Figure 1H ). Lesions with this pattern suggest a harboring Ha-ras mutations, the mutations were detected in either codon 12 (two carcinomas) or 13 (one carcinoma). mechanistic link between tumor progression and expression of p53 IHC. The buccal pouch mucosa of individual control However, mutations were also identified in codons 7 (three carcinomas), 60 (one carcinoma) and 63 (one carcinoma). hamsters, evaluated at 3 days and 7 weeks following the last For tumor no.: bold, p53 and Ha-ras mutation analyses performed; underlined, tumors exhibiting p53 mutation(s) within exons 5-8; italic, tumors exhibiting Ha-ras mutation(s). A total of 37 MBN-induced hamster buccal pouch 34 (92%) of these tumors (Table II) HBP epithelium.
Discussion carcinomas of the head and neck (38, 39, 47, 50) . p53 mutations and persistent p53 IHC activity were observed in 32 and 50% This study examined the frequency of telomerase activation, distribution of p53 IHC activity and the character and genomic of the carcinomas examined, respectively. Ha-ras mutations were observed in Ͻ15% of the buccal pouch carcinomas distribution of p53 and Ha-ras mutations in HBPCs induced by topical application of MBN. The pattern of p53 IHC activity examined. Whereas Ha-ras mutational activation is reportedly common in Asian populations wherein chewing tobacco is a and its persistence were examined in both precancerous and malignant MBN-induced lesions.
major risk factor (37), Ha-ras mutations are much less common in Western populations whose head and neck carcinomas are Telomerase activation was demonstrated in 34 of 37 (92%) of the HBPC examined. This frequency of carcinomas exhibiting most frequently attributable to the use of tobacco products and alcoholic beverages (51-54). Similarly, the frequency of p53 telomerase activation is comparable with that observed in mutations in head and neck cancers is high in populations frequency of 35% observed in an earlier study undertaken with this model (33) and approximates that of 40-50% using tobacco products and alcoholic beverages (35, 36, 55, 56) , but comparatively low in populations where these specific risk reported for human head and neck cancers (35, 36, 55, 56, 62) . Additional p53 mutations may have gone undetected in this factors are not strongly implicated (55, (57) (58) (59) (60) (61) p53 mutation was demonstrated in 32% of the buccal pouch tumors examined using SSCP and sequencing (Table II) . The frequency of p53 mutations observed is in agreement with the p53, Ha-ras and telomerase in hamster buccal pouch only~2% of all p53 mutations in carcinomas of the head and (65) to the 'hot-spot' codons 175, 245, 248 and 273, identified in human oral cancers and cancers of other head and neck neck (62). Many of the p53 mutations identified in the MBNinduced carcinomas occurred at or near codons corresponding locations (36, 62) . In this study, G→A transition mutations predominated (15/19 ϭ 79%), as is characteristic of mutations induced by MBN (66, 67) . G→A transitions are also the most common form of p53 mutations occurring in human head and neck cancer, including those of oral mucosa (35, 36, 62) . G→A transitions are also the predominant type of p53 mutation in esophageal carcinomas occurring in high risk areas of China (64, 68) , where MBN has been implicated as an environmentally derived agent contributing to this disease (69,70). p53 IHC activity was observed in the majority (81/89 ϭ 91%) of carcinomas harvested at day 3 post-MBN treatment and in 53 of the 105 (50%) carcinomas of the group B hamsters examined at 7 weeks following MBN exposure. The differences in frequency of p53 IHC expression between these groups is striking. Whereas wild-type p53 protein is rapidly degraded (72) and not usually detectable by IHC techniques, mutant forms are more stable (72, 73) , thus enabling detection by IHC (74-77). Stabilization of p53 protein secondary to mutation accounts for the frequent IHC detection of this protein in human neoplasms (64, (76) (77) (78) (79) (80) (81) (82) , including carcinomas of the head and neck (35, 36, 62, 82, 83) , and is the most likely determinant of the persistent p53 IHC activity observed in the present study at 7 weeks post-MBN treatment. Of the 45 group B tumors analyzed by both IHC and SSCP/DNA analysis, concordant results (i.e. both analyses either positive or negative) were observed in 29 (64%) of the carcinomas, according to the criteria selected for IHC positivity used in this study (i.e. 10% p53 and molecular confirmation of mutation reportedly ranges from~50 to 90% (36, 62, 82, 83) . It is also noteworthy that in this experimental group 11 of the 13 carcinomas (i.e. 85%) demonstrated that following systemic administration of MBN to rodents, bound metabolites of MBN reach maximum levels istic of oral cancers observed in cigarette smoking populations (53) . by approximately 3 days (42); (ii) the observed reduction in Telomerase activity was observed in 92% (34/37) of the the proportion of carcinomas exhibiting p53 staining between HBPC examined. In contrast to the temporal variation in levels 3 days and 7 weeks following the last MBN application is of p53 IHC expression observed, the metabolic perturbations likely a consequence of tissue metabolism and clearing of and toxicity related to recent MBN exposure appeared to MBN, with concomitant subsidence of DNA damage and have no effect on telomerase activation, since there was no repair and an accompanying reduction in the levels of induction appreciable difference in the level of telomerase activity or of wild-type p53; (iii) the D07 antibodies used to demonstrate the frequency of carcinomas exhibiting telomerase activity p53 overexpression in this study recognize wild-type as well between groups A and B (85 versus 96%). The high frequency as mutant forms of the p53 protein (43). In addition, there is of tumors exhibiting telomerase activation in this study parallels no evidence to suggest that overexpression of the endogenous that seen in human tumors (46) , including SCC of the oral protein mdm-2 contributes to p53 stabilization (76, 84) in the cavity and head and neck (38, 39, 46, 47, 50) . It has not been MBN-HBP model (33) . established in this model whether telomerase activation is As expected from the results of a previous study (22) , related to acquisition of the neoplastic phenotype per se or is histological examination of the flat to irregular mucosa a function of enhanced cell replication (114) or other persistent surrounding the MBN-induced carcinomas revealed a alterations resulting from carcinogen exposure. Whereas complete spectrum of hyperplastic, hyperkeratotic and ostensibly normal squamous mucosa usually lacks telomerase dysplastic lesions, as well as carcinomas in situ and microactivity (38, 115, 116) , it is frequently demonstrable in structural invasive SCC (see Figure 1) . The precancerous nature of precancerous lesions of the head and neck (38, 39, 47, 50, 115) . dysplastic lesions and carcinomas in situ is well established
In contrast to the corresponding malignant lesions, benign from clinico-pathological studies in man (105, 106) . In the neoplastic or hyperplastic lesions of uterus, prostate and breast present study, p53 IHC activity was observed in many of these characteristically lack telomerase activity (46, 117) . However, structural precancerous lesions and in many non-dysplastic in oral and other head and neck mucosal sites, telomerase sites within the MBN-exposed mucosa. Thus the pattern of activity has been demonstrated in benign hyperplastic lesions p53 staining in this animal model recapitulates those observed (50, 115) , as well as in presumptive precancerous lesions such as in structural precancerous lesions (64, 87, 97, (108) (109) (110) (111) , as well dysplasia (i.e. premalignant hyperplasia). In hyperplastic head as in high cancer risk non-dysplastic squamous mucosa in man and neck lesions with a strong inflammatory component, (64, 108, 111) . It is reasonable to hypothesize (112) that in both infiltrating lymphocytes should also be considered as a potential man and this hamster pouch model (33): (i) persistent intrasource of telomerase activity (118) . A recent study has sugepithelial p53 IHC lesions are material precursors for the gested a relationship between telomerase levels and levels of subsequent development of at least some of the carcinomas cell proliferation during HBP carcinogenesis mediated by the also exhibiting p53 IHC activity; (ii) that loss of p53 function polycyclic aromatic hydrocarbon 7,12-dimentlybenz[a]anthraplays a mechanistic role in the development of carcinomas.
cene (34). Additional studies are required to critically examine In normal squamous mucosa, DNA damage resulting from the role of telomerase activation in neoplastic progression carcinogen exposure leads to up-regulation of wild-type p53, versus hyperplasia, both in experimental models (119) and in which in turn contributes to inhibition of cell replication and head and neck carcinogenesis. apoptotic cell death (92, 113) . Presumably, mucosal sites lacking This study demonstrates molecular similarities between p53 function, such as those with persistent p53 IHC activity MBN-induced HBP lesions and the analagous human lesions resulting from p53 mutation, have a selective growth advantage of the head and neck. The proximal aerodigestive tract has many over the surrounding mucosa, resulting in their expansion characteristics which make this anatomical region amenable to during episodes of repeated carcinogen exposure and DNA development of novel strategies for cancer chemoprevention damage. According to this working hypothesis, cellular and therapy (1, (120) (121) (122) . Perhaps chief among these is the replication at these sites, in the face of continual carcinogenaccessibility of this anatomical region in general, and the oral mediated DNA damage, in turn increases the risk of acquiring mucosa in particular, for efficient delivery of chemopreventive additional mutational events leading to a malignant phenoand therapeutic agents and for effective clinical monitoring by type (112).
visualization, palpation and periodic tissue (or cytological) Ha-ras mutations were observed in eight of 60 (i.e. 13.3%) sampling. The mounting evidence of molecular similarities MBN-induced carcinomas. The frequency of MBN-induced between these two systems supports the MBN-HBP model as Ha-ras mutations observed here is in agreement with that of a promising in vivo system for testing potential therapeutic a previous study (33). Three of the 60 carcinomas in the agents and for the development of individual and combinational present study exhibited double mutations involving both the therapies directed at specific molecular targets. p53 (120,123-Ha-ras and p53 genes (see Table III ). Activating Ha-ras 127) and telomerase (128,129) have frequently been proposed mutations occur most commonly at codons 12 and 61 and as potential molecular targets for cancer chemotherapy. The potentially at codons 13, 59, 63, 116 and 119 (48, 49) . Only MBN-HBP model may be useful in the development of four of the eight observed Ha-ras mutations occurred at codons such novel chemopreventive and therapeutic modalities, by which have been shown to activate this oncogene (specifically, establishing their efficacy in vivo, prior to institution of two mutations at codon 12, one mutation at codon 13 and clinical trials. one mutation at codon 63) (see Table V ). The functional significance, if any, of the other four mutations observed atp53, Ha-ras and telomerase in hamster buccal pouch preparation of the manuscript. We also wish to thank Vanessa Jones, Gail biweekly to 7,12- 
